Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 169

Sort by

Sort Order Select

Journal Articles

Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 5167.

https://doi.org/10.1182/blood-2025-5167

Published: 2025

Journal Articles

Cladribine, idarubicin, and AraC (CLIA) combined with a FLT3 inhibitor in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A pooled analysis of prospective trials

Blood (2025) 146 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2025-1678

Published: 2025

Journal Articles

Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome

Blood (2025) 146 (Supplement 1): 997.

https://doi.org/10.1182/blood-2025-997

Published: 2025

Journal Articles

Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia

Roberta S. Azevedo, Naval Daver, Omer Karrar, Courtney DiNardo, Tapan Kadia, Musa Yilmaz, Gautam Borthakur, Ghayas Issa, Elias Jabbour, Xuelin Huang, Wei Qiao, Regina Abramova, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi, Nicholas Short

Blood (2025) 146 (Supplement 1): 45.

https://doi.org/10.1182/blood-2025-45

Published: 2025

Journal Articles

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Ghayas Issa, Hagop Kantarjian, Musa Yilmaz, Nicholas Short, Tapan Kadia, Georgina El Hajjar, Courtney DiNardo, Yesid Alvarado, Elias Jabbour, Gautam Borthakur, Naveen Pemmaraju, Farhad Ravandi, Michael Andreeff, Guillermo Garcia-Manero, Naval Daver

Blood (2025) 146 (Supplement 1): 3428.

https://doi.org/10.1182/blood-2025-3428

Published: 2025

Journal Articles

Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy

Sankalp Arora, Jayastu Senapati, Nicholas Short, Musa Yilmaz, Sanam Loghavi, Tapan Kadia, Courtney DiNardo, Gautam Borthakur, Joseph Jabbour, Hannah Goulart, Ghayas Issa, Naveen Pemmaraju, Wei-Ying Jen, Hussein Abbas, Michael Andreeff, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2025-3397

Published: 2025

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Blood (2025) 146 (Supplement 1): 592.

https://doi.org/10.1182/blood-2025-592

Published: 2025

Journal Articles

Luspatercept response predictors in lower-risk myelodysplastic syndrome

Vanthana Bharathi, Ian Bouligny, Emmanuel Almanza, Alex Bataller, Alexandre Bazinet, Wei-Ying Jen, Niranjan Khaire, Koji Sasaki, Danielle Hammond, Courtney DiNardo, Gautam Borthakur, Tapan Kadia, Naval Daver, Ghayas Issa, Musa Yilmaz, Kelly Chien, Guillermo Montalban-Bravo, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5648.

https://doi.org/10.1182/blood-2025-5648

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5228.

https://doi.org/10.1182/blood-2025-5228

Published: 2025

Journal Articles

Multiarm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias

Hannah Goulart, Caitlin Rausch, Elias Jabbour, Abhishek Maiti, David McCall, Naval Daver, Nicholas Short, Naveen Pemmaraju, Musa Yilmaz, Danielle Hammond, Steven Kornblau, Ghayas Issa, Branko Cuglievan, Farhad Ravandi, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 5204.

https://doi.org/10.1182/blood-2025-5204

Published: 2025

Journal Articles

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Mahesh Swaminathan, Nitin Jain, Alexandra Lovell, Ashley Dinh, Alessandra Ferrajoli, Jan Burger, Musa Yilmaz, Tapan Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Farhad Ravandi, Koji Sasaki, Wei Qiao, Zhouxuan Li, Naveen Garg, Michael Keating, William Wierda

Blood (2025) 146 (Supplement 1): 5687.

https://doi.org/10.1182/blood-2025-5687

Published: 2025

Journal Articles

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Jayastu Senapati, Elias Jabbour, Nitin Jain, Kelly Chien, Musa Yilmaz, Fadi Haddad, Guillermo Montalban-Bravo, Eitan Kugler, Wei-Ying Jen, Rita Khouri, Maro Ohanian, Rebecca Garris, Min Zhao, Guillermo Garcia-Manero, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 1573.

https://doi.org/10.1182/blood-2025-1573

Published: 2025

Journal Articles

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2025-1556

Published: 2025

Journal Articles

Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment

Caitlin Rausch, Gautam Borthakur, Fadi Haddad, Kelly Chien, Danielle Hammond, Guillermo Montalban-Bravo, Naveen Pemmaraju, Lucia Masarova, Musa Yilmaz, Michael Andreeff, Elias Jabbour, Jan Burger, Nitin Jain, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3457.

https://doi.org/10.1182/blood-2025-3457

Published: 2025

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Jennifer Marvin-Peek, Courtney D. DiNardo, Wei-Ying Jen, Nicholas J. Short, Yesid Alvarado Valero, Gautam Borthakur, Naval Daver, Eitan Kugler, Alexandre Bazinet, Hussein A. Abbas, Musa Yilmaz, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1472.

https://doi.org/10.1182/blood-2024-202405

Published: 2024

Journal Articles

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Akhil Jain, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Fadi G. Haddad, Naveen Pemmaraju, Nicholas J. Short, Maro Ohanian, Musa Yilmaz, Keyur P. Patel, Mark Brandt, Sherry Pierce, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur

Blood (2024) 144 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2024-211599

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia

Cladribine, idarubicin, and AraC (CLIA) combined with a FLT3 inhibitor in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A pooled analysis of prospective trials

Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome

Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Luspatercept response predictors in lower-risk myelodysplastic syndrome

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia

Multiarm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia

Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only